You are here

NKTR-102

Breast cancer drug, key to Nektar growth plans, fails clinical trial

Bizjournals.com

Tue, 03/17/15 - 07:23 pm

Nektar reports positive preclinical data for two oncology programs

The Fly on the Wall

Wed, 04/9/14 - 11:50 am

Nektar presents data from Phase l study of etirinotecan pegol

Yahoo/Fly on the Wall

Mon, 01/20/14 - 11:09 am

etirinotecan pegol

advanced cancer

2014 Looking Like A Big Year For Nektar

Seeking Alpha

Mon, 12/30/13 - 10:16 am

Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium

Yahoo/PR NewsWire

Sat, 09/10/11 - 09:59 am

NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil

Yahoo/PR NewsWire

Sun, 06/5/11 - 10:30 am

NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting

Yahoo/PR NewsWire

Sun, 06/5/11 - 10:24 am

topoisomerase I inhibitor

Nektar ovarian cancer drug gets FDA orphan status

Bizjournals.com

Thu, 04/21/11 - 06:53 pm